Comparison of Letrozole and Clomiphene Citrate Success Rate in Ovulation Induction
DOI:
https://doi.org/10.52206/jsmc.2026.16.1.1349Abstract
Background: Clomiphene citrate has traditionally been the first-line agent for ovulation induction; however, increasing evidence suggests that letrozole may offer superior efficacy with a more favorable endometrial profile. Comparative data examining treatment response across demographic and socioeconomic variables remain limited, especially within South Asian populations.
Objective: To compare the efficacy of letrozole and clomiphene citrate for ovulation induction in subfertile women with ovulatory dysfunction presenting to a tertiary care hospital in Khyber Pakhtunkhwa, Pakistan.
Methodology: This pilot randomized controlled trial was conducted from January to July 2024 in the Department of Gynecology and Obstetrics at Saidu Group of Teaching Hospital, Swat. A total of 64 subfertile women aged 18–30 years with anovulatory infertility were randomized in equal numbers to receive either letrozole 5 mg/day or clomiphene citrate 100 mg/day for five consecutive days, initiated between cycle days 3 and 5. Ovulation was monitored over three cycles using transvaginal ultrasonography, with biochemical confirmation using mid-luteal serum progesterone where applicable. The primary outcome was ovulation induction success.
Results: Baseline demographic and clinical characteristics were comparable between groups. Ovulation was achieved in 65.6% of women receiving letrozole compared with 37.5% of those receiving clomiphene citrate, representing a statistically significant difference (p = 0.024). Exploratory subgroup analyses suggested higher efficacy of letrozole among women with higher body mass index and selected socioeconomic subgroups.
Conclusion: In this pilot randomized controlled trial, letrozole demonstrated significantly higher ovulation induction efficacy compared with clomiphene citrate in subfertile women with ovulatory dysfunction. These findings support the growing evidence favoring letrozole as a first-line ovulation induction agent, while underscoring the need for larger multicenter trials evaluating pregnancy and live birth outcomes.
Keywords: Clomiphene citrate, Letrozole, Ovulation induction, Polycystic ovarian syndrome, Subfertility.
References
Carson SA, Kallen AN. Diagnosis and management of infertility: a review. JAMA. 2021;326(1):65–76. https://doi.org/10.1001/jama.2021.4788
Bonavina G, Taylor HS. Endometriosis-associated infertility: from pathophysiology to tailored treatment. Front Endocrinol (Lausanne). 2022;13:1020827. https://doi.org/10.3389/fendo.2022.1020827
Dennett CC, Simon J. The role of polycystic ovary syndrome in reproductive and metabolic health: overview and approaches for treatment. Diabetes Spectr. 2015;28(2):116–120. https://doi.org/10.2337/diaspect.28.2.116
Cunha A, Póvoa AM. Infertility management in women with polycystic ovary syndrome: a review. Porto Biomed J. 2021;6(1):e116. https://doi.org/10.1097/j.pbj.0000000000000116
Karnatak R, Agarwal A, Asnani M, Singh R. The effect of insulin resistance on ovulation induction with clomiphene citrate in non-polycystic ovary syndrome women. Cureus. 2022;14(7):e27433. https://doi.org/10.7759/cureus.27433
Vyrides AA, El Mahdi E, Giannakou K. Ovulation induction techniques in women with polycystic ovary syndrome. Front Med (Lausanne). 2022;9:982230. https://doi.org/10.3389/fmed.2022.982230
Sharma M, Balasundaram P. Ovulation induction techniques. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK574564/
Jirge PR, Patil MM, Gutgutia R, Shah J, Govindarajan M, Roy VS, et al. Ovarian stimulation in assisted reproductive technology cycles for varied patient profiles: an Indian perspective. J Hum Reprod Sci. 2022;15(2):112–125. https://doi.org/10.4103/jhrs.jhrs_59_22
Pajai S, Potdar J, Gopal U, Banait T. A review on the use of letrozole in female and male infertility. Cureus. 2022;14(11):e31291. https://doi.org/10.7759/cureus.31291
Neblett MF 2nd, Baumgarten SC, Babayev SN, Shenoy CC. Ovulation induction with letrozole and dexamethasone in infertile patients with letrozole-resistant polycystic ovary syndrome. J Assist Reprod Genet. 2023;40(6):1461–1466. https://doi.org/10.1007/s10815-023-02817-9
Quaas AM, Gavrizi SZ, Peck JD, Diamond MP, Legro RS, Robinson RD, et al. Endometrial thickness after ovarian stimulation with gonadotropin, clomiphene, or letrozole for unexplained infertility, and association with treatment outcomes. Fertil Steril. 2021;115(1):213–220. https://doi.org/10.1016/j.fertnstert.2020.07.030
Da Ros CT, Da Ros LU, Da Ros JPU. The role of clomiphene citrate in late-onset male hypogonadism. Int Braz J Urol. 2022;48(5):850–856. https://doi.org/10.1590/S1677-5538.IBJU.2021.0724
Hawkins Bressler L, Fritz MA, Wu SP, Yuan L, Kafer S, Wang T, et al. Poor endometrial proliferation after clomiphene is associated with altered estrogen action. J Clin Endocrinol Metab. 2021;106(9):2547–2565. https://doi.org/10.1210/clinem/dgab381
Liang Y, Guo Q, Wu XH, Zhang LN, Ge J, Xu ML, et al. Does the additional use of clomiphene citrate or letrozole for in vitro fertilization deserve more attention? BMC Pregnancy Childbirth. 2021;21(1):275. https://doi.org/10.1186/s12884-021-03668-x
Ashfaq A, Tahseen H, Noreen Z, Alam N. Clomiphene citrate vs letrozole in PCOS patients for ovulation induction. Pak J Med Health Sci. 2018;12(2):781–784.
Razzaq S, Rasheed S, Pansota MS, Fatima N. Efficacy in terms of orally administered letrozole versus clomiphene citrate in anovulatory infertility. Gomal J Med Sci. 2015;13(1):15–18.
Mobusher I. Comparison of the efficacy of letrozole and clomiphene citrate for ovulation induction in infertile women with polycystic ovary syndrome. Pak J Med Health Sci. 2014;8(4):905–908.
Wasim T, Nasrin T, Zunair J, Irshad S. Efficacy of letrozole versus clomiphene citrate for induction of ovulation in women with polycystic ovarian syndrome. Pak J Med Sci. 2024;40(1):78–83. https://doi.org/10.12669/pjms.40.1.7971
Shafiq A, Akbar R, Urooj U, Zohra S, Afzal S, Tanveer M. Comparison of ovulation induction with letrozole and clomiphene citrate in subfertile women with polycystic ovarian syndrome. Pak Armed Forces Med J. 2021;71(5):1844–1847. https://doi.org/10.51253/pafmj.v71i5.6554
Khakwani M, Parveen R, Yousaf S, Tareen AU. Efficacy of letrozole versus clomiphene citrate on ovulation induction in patients with polycystic ovarian syndrome. Pak J Med Sci. 2022;38(5):1155–1158. https://doi.org/10.12669/pjms.38.5.5565
Ilangovan S. A comparative study of letrozole and clomiphene citrate for ovulation induction in women with polycystic ovarian syndrome: a randomized controlled trial. Int J Reprod Contracept Obstet Gynecol. 2024;13(8):1999–2003. https://doi.org/10.18203/2320-1770.ijrcog20241954
Begum P, Shaha DR, Hassan MK, Zeba D. Efficacy and side effects of letrozole over clomiphene citrate for ovulation induction in patients with PCOS: a randomized controlled trial. Faridpur Med Coll J. 2020;15(2):69–73. https://doi.org/10.3329/fmcj.v15i2.53891
Zafar T, Asif F, Naurin R, Majeed T, Mahmood Z. Comparing effectiveness of letrozole versus clomiphene citrate to evaluate ovulation induction in patients with polycystic ovarian syndrome. Pak J Med Health Sci. 2021;15(10):2685–2688. https://doi.org/10.53350/pjmhs2115102685
Khan UY, Mehwish M, Nafees S, Raishem R, Mushtaq S, Nafees S. Comparison of clomiphene citrate and letrozole in induction of ovulation among patients with polycystic ovarian syndrome and primary subfertility. J Soc Obstet Gynaecol Pak. 2025;15(1):6–11. https://doi.org/10.71104/jsogp.v15i1.871
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 The authors retain the copyrights. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on their website), as it can lead to productive exchanges, as well as greater citation of published work.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
